Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for determining the risk of preeclampsia using pigf-2 and pigf-3 markers

A technology of pre-eclampsia and markers, applied in the field of using PIGF-2 and PIGF-3 markers to determine the risk of pre-eclampsia, which can solve the problems of non-adoption of pre-eclampsia

Inactive Publication Date: 2011-10-19
PERKINELMER HEALTH SCIENCES INC +2
View PDF1 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Nonetheless, there is currently no routine screening for the early detection of preeclampsia using maternal samples

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for determining the risk of preeclampsia using pigf-2 and pigf-3 markers
  • Method for determining the risk of preeclampsia using pigf-2 and pigf-3 markers
  • Method for determining the risk of preeclampsia using pigf-2 and pigf-3 markers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0159] This example describes that levels of PlGF-2 in maternal serum are increased in subjects who develop preeclampsia, while levels of PlGF-3 in maternal serum are decreased in subjects who develop preeclampsia.

[0160] To measure (a) PlGF-2; (b) PlGF-3; and (c) combinations of PlGF-1, PlGF-2, and PlGF-3, a PlGF isoform-specific DELFIA sandwich assay was established.

[0161] PlGF isoforms were measured in serum obtained from pregnant women who subsequently developed preeclampsia and pregnant women who did not develop preeclampsia. Blood samples were drawn twice from each woman: once during the first trimester of pregnancy and a second time during the second trimester. Blood tubes were centrifuged and serum was collected and aliquoted. These aliquots were stored at -20°C. Selected unaffected pregnancy controls were matched to preeclamptic pregnancy cases by biophysical parameters such as maternal age, body mass index, race, and gestational age. PlGF-2 and PlGF-3 concent...

Embodiment 2

[0175] This method shows that commercially available PlGF-1 assays are cross-reactive with other PlGF isoforms.

[0176] PlGF-1 was analyzed using the commercial DELFIA Xpress PlGF method (PerkinElmer), with samples prepared to contain known amounts of purified recombinant PlGF isoforms, including recombinant PlGF-1 (non-glycosylated). As expected, the highest PlGF-1 was observed for the PlGF-1 antibody provided with the DELFIA Xpress kit (Table 2). However, significant cross-reactivity with PlGF-2 isoforms and some cross-reactivity with PlGF-3 isoforms was also observed. Therefore, this method mainly detects PlGF-1 and is not specific.

[0177] Other manufacturers have observed similar results with their current PlGF-1 approach. For example, R&D Systems reports in their method specification that their Quantikine Human PlGF ELISA Kit is 50% cross-reactive with PlGF-2 when measured against standards prepared from PlGF-1. Roche reports in their method specification that their E...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for determining the risk of a pregnant woman developing pre-eclampsia. The method comprises i) determining the level of one or more biochemical markers in a sample obtained from a pregnant woman, and ii) comparing the level of the at least one biochemical marker in the sample with the level of the same biochemical marker in a control sample. A difference in the level of the biochemical marker in the sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia. The isoform biochemical markers are preferably PlGF-2 and PlGF-3. The present invention relates also to a method for determining whether a pregnant woman has pre-eclampsia and as well as a kit for assessing the risk or presence of pre-eclampsia. In addition, the invention relates also to a computer program used in these determinations.

Description

Background of the invention [0001] Worldwide, at least 126 million women give birth every year. More than 20 million of them will suffer pregnancy-related complications or diseases. For example, hypertension, such as preeclampsia (PE), affects more than 10% of all pregnant women and is the leading cause of maternal death. Adequate prenatal care reduces the chances of such complications and diseases going undetected. Even so, currently there is no routine screening for the early detection of preeclampsia using maternal samples. If the onset of PE, especially early-onset PE, could be detected earlier, it would be possible to obtain better outcomes, including reduced severity and even recovery in many cases. A reliable method for assessing the risk of developing PE or assessing the presence of PE during the first or third trimester would reduce the likelihood of negative health outcomes for the mother, baby, or both. [0002] A number of biomarkers present in maternal samples...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G16B50/00
CPCG01N33/689G01N2800/368G16B50/00
Inventor 塔加·阿霍拉海尼·弗朗缇姆·科皮玛吉佩蒂·胡尔斯凯宁马克·N·波布罗乔纳森·B·卡米歇尔
Owner PERKINELMER HEALTH SCIENCES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com